Online Pet Medications & Pet Supplies

Equimidine 15Ml

   Product Ref: DUEQU18 Category: C

£ 232.45

Vat Rate: 20%

Prescription Required

Equimidine has sedative and analgesic properties and is indicated for use either alone or in combination with butorphanol to facilitate the handling of horses for clinical examinations, minor surgical procedures and other manipulations. It can also be used with ketamine for short duration general anaesthesia appropriate for short surgical procedures such as castration.
Vat Rate: 20%

Our Standard Delivery - £6.75

Royal Mail Tracked 24 (Signed For)

  • Next business day service
  • Compensation cover up to £100
  • Signature on delivery


Any orders placed after close of business on Thursday will not be delivered until Tuesday




Our Express Delivery - £10.45

Royal Mail Special Delivery Guaranteed by 1pm

  • Next business day service
  • Insured up to £500
  • Signature on delivery


Please note that all chilled deliveries must be sent on an Express service.

Chilled orders placed after close of business on Wednesday will not be despatched until Monday

You must be logged in to write review
Category POM-V
Temperature Ambient
MA/VM/EU No: 25929/4000
  • horses
VMD Link
Dosage For SLOW intravenous administration only. As this is a multi-dose bottle the surface of the bung should be cleaned and disinfected prior to penetration of the bung with a sterile needle. The needle should be passed carefully into the bottle prior to withdrawal of the dose and then withdrawn carefully to avoid damage (see also operator warnings below). The following procedure is recommended: Use two sterile needles, one to fill the syringe from the bottle and one to inject the patient; once the required dose has been withdrawn from the vial, the syringe should be removed from the needle; a separate sterile needle should be inserted into the injection site and the syringe connected to it; the needles should be discarded. Return bottle to cardboard carton after use. Equimidine alone for sedation - Dosage Table: Anticipated Level of Sedation Light Moderate Profound Dosage (I/V) mcg/kg 10 - 20 20 - 40 40 - 80 Dose (I/V) ml/100 kg 0.1 – 0.2 0.2 – 0.4 0.4 – 0.8 Commencement of effect (mins) 3 2 1 Duration of action (hrs) 0.5 – 1 0.5 – 1 0.5 – 2 Equimidine with butorphanol for sedation: Dosage 0.12 ml Equimidine/100 kg (12 mcg/kg detomidine hydrochloride) intravenously followed within 5 minutes by 25 mcg/kg butorphanol (e.g. 0.25 ml/100 kg of a 10 mg/ml solution) intravenously. Clinical experience has shown that 5 mg detomidine hydrochloride (0.5 ml Equimidine) and 10 mg (e.g. 1 ml of a 10 mg/ml solution) of butorphanol affords effective and very safe sedation in horses above 200 kg bodyweight. Equimidine with ketamine (short duration anaesthesia): Ketamine should not be used as the sole anaesthetic agent in horses. It is important to adhere to the following procedures to obtain satisfactory surgical anaesthesia. Administer Equimidine at a dose rate of 20 mcg/kg by slow intravenous injection. Allow 5 minutes for the horse to become deeply sedated then administer ketamine at a dose rate of 2.2 mg/kg as an intravenous bolus. Onset of anaesthesia is gradual with the horse taking approximately 1 minute to become recumbent (in large fit horses recumbency may take up to 3 minutes). Anaesthesia will deepen for a further 1-2 minutes and during this time the horse should be left quietly. Horses regain sternal recumbency approximately 20 minutes after ketamine injection. The period of surgical anaesthesia is about 10-15 minutes and if it is necessary to prolong anaesthesia, thiopentone sodium can be given as intravenous boluses of 1 mg/kg as required. Total doses of 5 mg/kg (5 x 1 mg/kg injections) have been given. Doses greater than this may reduce the quality of recovery. Thiopentone can also be given (as above) to deepen the anaesthesia if needed. The horse should be allowed to stand in its own time. Ataxia may be a problem if it stands prematurely and it should be encouraged to remain recumbent. To facilitate handling and administration some horses have received acepromazine by intramuscular injection at a dose rate of 0.03 mg/kg at least 45 minutes prior to induction of anaesthesia.
Withdrawals Before using any combination read the contra-indications and warnings appearing on the other product’s information sheets (datasheet, Summary of the Product Characteristics (SPC) or package leaflet). Do not use with sympathomimetic amines. Do not use in the last 3 months of pregnancy. Use only according to a benefit/risk assessment by the responsible veterinary surgeon during the other months of pregnancy. Do not use with potentiated sulphonamide drugs. Do not mix with other products. Do not use in horses with cardiac abnormalities (including pre-existing AV blocks and coronary insufficiency) or respiratory disease. Do not use in horses with liver insufficiency or renal failure. Do not use in horses with general health problems (eg dehydration). Do not use in combination with butorphanol in horses suffering from colic. Do not offer food or water until drug effect has passed. Use with care with other sedatives and anaesthetics because of an additive/synergistic effect. Detomidine should not be used in combination with sympathomimetic amines such as adrenaline, dobutamine and ephedrine. Administration of Equimidine may cause the following side effects: bradycardia, transient hypo- and/or hypertension, respiratory depression, rarely hyperventilation, increase in blood glucose, sweating, ataxia, uterine contractions cardiac arrhythmia, atrioventricular and sino-atrial block. As with other sedatives, in rare cases paradoxical reactions (excitations) can develop. At doses above 40 mcg/kg bodyweight sweating, pilo-erection, muscle tremors and transient penis prolapse has been observed. In very rare cases, horses may show mild symptoms of colic following administration of alpha-2 sympathomimetics, as these substances transiently inhibit intestinal mobility. Detomidine should be used with caution in horses which present with signs of colic or impaction. A diuretic effect is usually observed within 45 to 60 minutes of treatment. Equimidine with butorphanol for sedation: Do not use in horses with a history of liver disease. This combination should not be used in pregnant mares or in animals suffering from colic. Routine cardiac auscultation should be performed prior to use of this combination. Do not use in horses with pre-existing cardiac dysrhythmia or bradycardia. Mild to severe ataxia may be encountered but clinical studies have shown that horses are unlikely to collapse. Normal precautions should be taken to prevent patient self injury. Equimidine with ketamine (short duration anaesthesia): Allow sedation to develop. The two agents should never be co-administered in the same syringe. It is recommended that feed is withdrawn for at least 12 hours prior to anaesthesia. Excitable horses can be poor subjects for anaesthesia. Considerate, quiet and careful handling during the administration of agents is necessary to cause the minimum upset possible. If sedation with Equimidine fails to occur then the procedure should be abandoned. In these circumstances ketamine must not be injected into the horse. Withdrawal period Meat and offal: 2 days. Milk: 12 hours. Operator Warnings In the case of accidental oral intake or self-injection, seek medical advice immediately and show the package leaflet to the physician but DO NOT DRIVE as sedation and changes in blood pressure may occur. Avoid skin, eye or mucosal contact. The use of impermeable gloves is advisable especially in the case of damaged skin. Immediately after exposure wash the exposed skin with large amounts of fresh water. Remove contaminated clothes that are in direct contact with the skin. In the case of accidental contact of the product with eyes, rinse with large amounts of fresh water. If symptoms occur, seek the advice of a doctor. If pregnant women handle the product, special caution should be observed not to self-inject as uterine contractions and decreased foetal blood pressure may occur after accidental systemic exposure. ADVICE TO DOCTORS: Detomidine is an alpha-2-adrenoreceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia and hypotension, a dry mouth and hyperglycaemia. Ventricular arrhythmias have also been reported. Respiratory and haemodynamic symptoms should be treated symptomatically.